The mutation rate of the Omicron sublineage has led to baseline resistance against all
previously authorized anti-Spike monoclonal antibodies (mAbs). Nevertheless, in case more …

Effective treatments and vaccines against COVID-19 used in clinical practice have made a
positive impact on controlling the spread of the pandemic, where they are available …

As of May 2022, there have been over 524 million confirmed cases of COVID-19 (10). The
pandemic has thus far claimed approximately 6.2 million lives (10). Vaccination is having a …

Background Outpatient monoclonal antibodies are no longer effective and antiviral
treatments for coronavirus disease 2019 (COVID-19) disease remain largely unavailable in …

Background The role of host immunity in emergence of evasive SARS-CoV-2 Spike
mutations under therapeutic monoclonal antibody (mAb) pressure remains to be explored …

The evolution of SARS-Coronavirus-2 (SARS-CoV-2) has been characterized by the
periodic emergence of highly divergent variants. One leading hypothesis suggests these …

Portable assays for the rapid identification of lineages of severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) are needed to aid large-scale efforts in monitoring the …

Background Antiviral and antibody therapies for severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) are being recommended for high-risk patients, but the potential …

COVID-19 has stimulated the rapid development of new antibody and small molecule
therapeutics to inhibit SARS-CoV-2 infection. Here we describe a third antiviral modality that …

The objective of this review was to examine the latest literature regarding the effectiveness
of monoclonal antibodies as COVID-19 prophylaxis therapy for immunocompromised patient …